Skip to main content

Table 3 Serum phospholipid fatty acids composition in the study patients

From: Relationship between polyunsaturated fatty acid composition in serum phospholipids, systemic low-grade inflammation, and glycemic control in patients with type 2 diabetes and atherosclerotic cardiovascular disease

Fatty acid

HbA1c < 7.0%

n = 38

HbA1c ≥ 7.0%

n = 36

p value

SFAs

 C12:0 (µmol/l)

1.73 (1.14; 2.84)

2.25 (1.39; 3.31)

0.17

 C14:0 (µmol/l)

16.20 (15.09; 18.12)

18.31 (14.37; 20.92)

0.18

 C16:0 (µmol/l)

940.62 (833.71; 1022.22)

973.60 (868.19; 1074.23)

0.50

 C18:0 (µmol/l)

421.96 ± 92.87

439.14 ± 96.71

0.44

 C24:0 (µmol/l)

24.17 (19.31; 28.40)

24.695 (20.38; 30.34)

0.99

MUFAs

 C16:1 (µmol/l

15.06 (12.33; 21.72)

14.56 (12.00; 19.79)

0.60

 C18:1 (µmol/l)

270.77 (244.27; 332.28)

285.625 (246.25; 336.565)

0.75

n-3 PUFAs

 C18:3; ALA (µmol/l)

5.75 (4.73; 8.48)

7.21 (5.22; 8.94)

0.26

 C20:5; EPA (µmol/l)

71.66 (48.65; 90.31)

48.55 (38.96; 66.86)

0.002

 C22:6; DHA (µmol/l)

303.11 (241.62; 355.04)

263.25 (208.77; 325.18)

0.07

n-6 PUFAs

 C18:2; LA (µmol/l)

421.46 (343.43; 476.27)

471.02 (402.46; 546.30)

0.02

 C20:2 (µmol/l)

16.39 (13.24; 18.33)

18.21 (14.39; 22.26)

0.14

 C20:4; AA (µmol/l)

542.03 ± 95.38

561.92 ± 154.30

0.51

Total SFAs (µmol/l)

1439.66 ± 288.90

1431.66 ± 282.75

0.90

Total MUFAs (µmol/l)

286.15 (260.18; 356.12)

308.95 (261.43; 357.57)

0.77

Total n-3 PUFAs (µmol/l)

378.16 (296.06; 436.75)

320.70 (260.36; 396.61)

0.02

Total n-6 PUFAs (µmol/l)

986.24 ± 171.11

1065.54 ± 210.49

0.08

Total FAs (µmol/l)

3088.55 (2785.20; 3413.38)

3148.76 (2748.18; 3519.32)

0.65

n-6/n-3 ratioa

2.69 ± 0.78

3.32 ± 0.83

0.001

EPA/AA ratio

0.13 (0.07; 0.14)

0.10 (0.07; 0.12)

0.008

DHA/AA ratio

0.13 (0.09; 0.17)

0.50 (0.41; 0.59)

0.15

  1. Data are given as number (percentage) for categorical variables and mean (± standard deviation) or median (IQR) for continuous variables
  2. Italic values indicate significance of p value (p < 0.05)
  3. AA arachidonic acid, ALA alpha-linolenic acid, DHA docosahexaenoic acid, EPA eicosapentaenoic acid, FAs fatty acids, LA linoleic acid, MUFAs monounsaturated fatty acids, PUFAs polyunsaturated fatty acids, SFAs saturated fatty acids
  4. aThe n-6/n-3 fatty acid ratio was calculated by measuring: linoleic, C18:2n-6; eicosadienoic, C20:2n-6; arachidonic, C20:4n-6 acids to estimate total n-6 PUFAs and alpha-linolenic, C18:3n-3; eicosapentaenoic, C20:5n-3; docosahexaenoic, C22:6n-3 acids to estimate the total n-3 PUFAs
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840